semaglutide 50 mg tablet Novo Nordisk wins EU approval for Wegovy weight-loss pill Eligible Medicare Part D Members

Published Phase 2 trial data (for example, Jastreboff et al., NEJM 2023) have explored doses ranging from approximately 1 mg up to 12 mg administered once weekly

Patients interested in access should speak with their GP or obesity medicine specialist about eligibility for ongoing MHRA-authorised clinical trials

However, many people may not be aware of the changes theyll likely experience in the days and weeks after they stop taking these medications, especially for those who quit cold turkey

For those without insurance, manufacturer savings programs may be available to help offset costs, and our Klinic team is here to explore all your options

Contrary to what some influencers on TikTok and Instagram might suggest, you dont simply inhale a squirt of tanning spray before bed and poof